JUVA LIFE INC - JUVAF STOCK NEWS

Juva Life Inc. (CSE: JUVA) (OTCQB: JUVAF) has launched its first in-house branded product, the Secret Sauce concentrate line, aiming to diversify into high-growth product categories. CEO Doug Chloupek states this move capitalizes on the growing market for cannabis concentrates, which currently holds 26.6% of market share. The product will be distributed through Juva Delivery and retail partnerships across California. Additionally, Juva has filed patents for non-cannabinoid compounds JUVA-019 and JUVA-041, showing promise in their preclinical research for pain and inflammation control.

Juva Life Inc. (OTCQB: JUVAF) recently held a corporate update webinar discussing significant milestones and future plans. The completion of the Stockton cultivation facility has tripled output without increasing production costs. The company also announced operational milestones, including the launch of Stockton Delivery and the final licensing phase for a Redwood City retail store. Advancements were noted in R&D, particularly for proprietary compounds JUVA-019 and JUVA-041, along with WIRB approval for the JuLi Research Registry.

Juva Life Inc. has completed the final phase of construction at its 30,000-square-foot cannabis cultivation facility in Stockton, California, effectively doubling its capacity. This expansion, costing $2.6 million, brings the total construction cost to $12.5 million. The facility will increase cannabis flower cultivation rooms from three to six. Juva aims for 33 planned harvests in 2022, with a target yield of 2-2.5 pounds per light. A live Zoom webinar will occur on March 23 to discuss updates.

Juva Life Inc. (CSE: JUVA) (OTCQB: JUVAF) has launched a new Journal App aimed at helping cannabis users track the effects of their consumption on health and wellness. This innovative tool allows users to document symptoms and medication usage, contributing to a larger database of real-world cannabis data. Juva’s CEO highlighted the app's role in advancing scientific understanding of cannabis while ensuring user anonymity and privacy. The company is also conducting a multi-year study on cannabis efficacy, aiming to leverage findings for regulatory purposes.

Juva Life Inc. (CSE: JUVA) (OTCQB: JUVAF) has filed a patent application with the USPTO for JUVA-041, a non-cannabinoid molecule aimed at treating inflammation. This follows the previous patent filing for JUVA-019, highlighting the company's commitment to developing safe, effective anti-inflammatory drugs. CEO Doug Chloupek emphasized that these compounds avoid regulatory issues associated with THC, marking a key development in the company's pharmaceutical strategy. Juva aims to partner with leading firms for further product development.

Juva Life Inc. (CSE: JUVA) (OTCQB: JUVAF) has advanced its non-cannabinoid drug candidate JUVA-041 into pre-clinical development. Identified through a unique discovery strategy, JUVA-041 exhibits potent anti-inflammatory properties sufficient for industry-standard testing. CEO Doug Chloupek remarked on the significance of non-cannabinoid compounds in cannabis research, aiming for IND filing after further testing. Juva is committed to leveraging its revenue from retail to support ongoing pharmaceutical development.

Juva Life Inc. announced the advancement of JUVA-019 into pre-clinical development, a non-cannabinoid molecule showing strong anti-inflammatory properties. Verified studies affirm that JUVA-019 operates effectively without cannabinoids. The next phase involves exploring structure-activity relationships and pharmacokinetics in various disease models, initially targeting analgesia. The global anti-inflammatory therapeutics market is projected to reach USD $191.4 billion by 2027, highlighting the commercial potential of JUVA-019.

Juva Life has launched the first nationwide cannabis registry in the U.S., named the IMPACT Registry, approved by WCG IRB. This initiative aims to collect real-world data on the health benefits of cannabis for conditions like chronic pain and anxiety. Open to patients over 21, it will assess the effectiveness of various cannabis products and their potential to reduce opioid use. Juva expects to leverage this data for clinical research and regulatory submissions. The study is available to patients in California and nationwide for CBD products.

Juva Life Inc. (CSE: JUVA) (OTCQB: JUVAF) reported strong Q3 2021 results, with revenues soaring by 322% year-over-year to $1.2 million and a significant 390% increase for the nine-month period, totaling $2.5 million. Gross profit for Q3 reached $0.51 million, representing 43.1% of revenue. Additionally, total net expenses decreased from $3.1 million to $2.5 million. The company is expanding its pharmaceutical research initiatives and has nominated JUVA-019 for further study due to its significant anti-inflammatory properties, enhancing its position in the cannabis research sector.